Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Broccoli compound may shield hearts from chemo damage

NCT ID NCT03934905

Disease control Sponsor: Texas Tech University Health Sciences Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This trial investigates whether sulforaphane, a nutrient found in broccoli, can reduce heart damage caused by the chemotherapy drug doxorubicin in breast cancer patients. About 70 participants will receive either sulforaphane or a placebo alongside their chemotherapy. The study measures changes in heart function and signs of heart injury to see if the supplement offers protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
sulforaphane (a nutrient found in broccoli and other cruciferous vegetables)
What this could lead to
If it works, this could lead to a simple dietary supplement that helps prevent heart damage from a common chemotherapy drug, improving safety for breast cancer patients.
What could go wrong
This is an early-phase trial with only 70 participants, so results may not apply to everyone. The supplement may not protect the heart or could interact with chemotherapy in unexpected ways.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2022

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 89 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18 to 89 years 2. No prior diagnosis of coronary artery, carotid artery or peripheral artery disease 3. Not pregnant or breastfeeding (urine pregnancy test will be done if female of childbearing potential) 4. Breast cancer requiring treatment with DOX-containing regimen above 5. Women in child bearing age group (18-50 years) will agree to use birth control for duration of study 6. Study subjects must be willing and able to swallow caplets, up to 8 daily. Exclusion Criteria: 1. Currently on a research study with an investigational drug, or has been on one in the previous 30 days 2. Pregnant (by urine pregnancy test) 3. Baseline ejection fraction of less than 50%, evidence of left ventricular hypertrophy or baseline EKG reported as abnormal per cardiologist. 4. Inability to provide informed consent. 5. Prior history of chest radiation therapy 6. Diabetes or Hypertension or prior Myocardial infarction 7. Trastuzumab patients 8. Routinely taking vegetable or fruit-containing supplement pills (antioxidant phytochemicals) (daily vitamin pills ok) 9. Inability to follow up for safety monitoring 10. Prisoners 11. Previous or current use of cocaine or any illicit drug 12. Unable or unwilling to provide blood samples 13. Taking medications known to have cardiac effects, such as but not limited to, beta blockers, anti-arrhythmic agents, non dihydropyridine calcium channel blockers, ace inhibitors, NSAIDS, diuretic agents. 14. Unable to follow the protocol 15. Inability to receive anthracycline due to any reason (underlying baseline cardiac dysfunction due to other reasons, with an EF under 50%) 16. Patients already taking SFN OTC

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anthracycline related cardiotoxicity in breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer cardiomyopathy due to anthracyclines Cardiotoxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anthracycline related cardiotoxicity in breast cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Texas Tech University Health Sciences Center

    RECRUITING

    Lubbock, Texas, 79430, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.